Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410X.2006.06357_3.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review on emerging pharmaceutical residues in Ethiopia: occurrence, ecotoxicological aspects, and regulatory concerns.
Front Microbiol
December 2024
Jimma University Laboratory of Drug Quality (JuLaDQ) and School of Pharmacy, Jimma University, Jimma, Oromia, Ethiopia.
Background: Pharmaceuticals are expected to improve human and animal health, but improper management and regulation have led to adverse effects such as reproductive disorders, antibiotic resistance, and biodiversity loss in ecosystems. Their presence in the environment poses significant risks, including a reduction in biodiversity, reproductive issues, and the development of antimicrobial resistance. This review aims to examine the occurrence and sources of pharmaceuticals in the environment and their ecotoxicological and regulatory aspects, with a focus on Ethiopia.
View Article and Find Full Text PDFFeasibility and predictive factors on the completion of docetaxel plus S-1 adjuvant chemotherapy in pathological stage III gastric cancer.
Ann Gastroenterol Surg
January 2025
Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital Japanese Foundation for Cancer Research Tokyo Japan.
Background: The standard adjuvant chemotherapy regimen for stage III gastric cancer is docetaxel plus S-1 (DS) based on the results of the START-II trials. However, in clinical practice some patients could not continue this intensive doublet chemotherapy because of limited tolerability. This study aimed to assess the practical feasibility of DS and elucidate the predictive factors for the completion of adjuvant DS therapy.
View Article and Find Full Text PDFRecent advances of antibody-drug conjugates in treating breast cancer with different HER2 status.
Ther Adv Med Oncol
January 2025
Department of General Surgery, The First Affiliated Hospital of Soochow University, No. 899, Pinghai Road, Suzhou, Jiangsu 215006, China.
Despite the availability of multiple treatment options for breast cancer, challenges such as adverse events, drug resistance, and disease progression persist for patients. The identification of human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers, alongside the development of HER2-targeted therapies, has significantly improved the prognosis of HER2-amplified breast cancers. However, therapeutic options remain limited for HER2-overexpressing or HER2-negative breast cancers.
View Article and Find Full Text PDFInnovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy.
Ther Adv Med Oncol
January 2025
Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan 20141, Italy.
Antibody-drug conjugates (ADCs) have emerged as a transformative approach in cancer therapy by enhancing tumor targeting and minimizing systemic toxicity compared to traditional chemotherapy. Initially developed with chemotherapy agents as payloads, ADCs have now incorporated alternative payloads, such as immune-stimulating agents, natural toxins, and radionuclides, to improve therapeutic efficacy and specificity. A significant advancement in ADC technology is the integration of Proteolysis Targeting Chimeras (PROTACs), which enable the precise degradation of cellular targets involved in tumorigenesis.
View Article and Find Full Text PDFBurning Mouth Syndrome From Statin Use: A Case Study.
Cureus
December 2024
Neurology, University of Pittsburgh Medical Center Hamot, Erie, USA.
Statins are one of the most commonly prescribed medications in America. They are known for their ability to decrease cholesterol. Although generally well-tolerated, they are known to cause a variety of moderate side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!